Enhancement of BDNF expression and memory by HDAC inhibition requires BET bromodomain reader proteins

Gregory C. Sartor, Andrea M. Malvezzi, Ashok Kumar, Nadja S. Andrade, Hannah J. Wiedner, Samantha J. Vilca, Karolina J. Janczura, Amir Bagheri, Hassan Al-Ali, Samuel K. Powell, Peyton T. Brown, Claude H. Volmar, Thomas C. Foster, Zane R Zeier, Claes R Wahlestedt

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Histone deacetylase (HDAC) inhibitors may have therapeutic utility in multiple neurological and psychiatric disorders, but the underlying mechanisms remain unclear. Here, we identify BRD4, a BET bromodomain reader of acetyl-lysine histones, as an essential component involved in potentiated expression of brain-derived neurotrophic factor (BDNF) and memory following HDAC inhibition. In in vitro studies, we reveal that pharmacological inhibition of BRD4 reversed the increase in BDNF mRNA induced by the class I/IIb HDAC inhibitor suberoylanilide hydroxamic acid (SAHA). Knock-down of HDAC2 and HDAC3, but not other HDACs, increased BDNF mRNA expression, whereas knock-down of BRD4 blocked these effects. Using dCas9-BRD4, locus-specific targeting of BRD4 to the BDNF promoter increased BDNF mRNA. In additional studies, RGFP966, a pharmacological inhibitor of HDAC3, elevated BDNF expression and BRD4 binding to the BDNF promoter, effects that were abrogated by JQ1 (an inhibitor of BRD4). Examining known epigenetic targets of BRD4 and HDAC3, we show that H4K5ac and H4K8ac modifications and H4K5ac enrichment at the BDNF promoter were elevated following RGFP966 treatment. In electrophysiological studies, JQ1 reversed RGFP966-induced enhancement of LTP in hippocampal slice preparations. Last, in behavioral studies, RGFP966 increased subthreshold novel object recognition memory and cocaine place preference in male C57BL/6 mice, effects that were reversed by cotreatment with JQ1. Together, these data reveal that BRD4 plays a key role in HDAC3 inhibitor-induced potentiation of BDNF expression, neuroplasticity, and memory.

Original languageEnglish (US)
Pages (from-to)612-626
Number of pages15
JournalJournal of Neuroscience
Volume39
Issue number4
DOIs
StatePublished - Jan 23 2019

Fingerprint

Histone Deacetylases
Brain-Derived Neurotrophic Factor
Proteins
Histone Deacetylase Inhibitors
Messenger RNA
Pharmacology
Inhibition (Psychology)
Neuronal Plasticity
Nervous System Diseases
Inbred C57BL Mouse
Cocaine
Epigenomics
Histones
Lysine
Psychiatry
RGFP966

Keywords

  • BDNF
  • BET
  • BRD4
  • Bromodomain
  • HDAC3
  • JQ1

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Enhancement of BDNF expression and memory by HDAC inhibition requires BET bromodomain reader proteins. / Sartor, Gregory C.; Malvezzi, Andrea M.; Kumar, Ashok; Andrade, Nadja S.; Wiedner, Hannah J.; Vilca, Samantha J.; Janczura, Karolina J.; Bagheri, Amir; Al-Ali, Hassan; Powell, Samuel K.; Brown, Peyton T.; Volmar, Claude H.; Foster, Thomas C.; Zeier, Zane R; Wahlestedt, Claes R.

In: Journal of Neuroscience, Vol. 39, No. 4, 23.01.2019, p. 612-626.

Research output: Contribution to journalArticle

Sartor, GC, Malvezzi, AM, Kumar, A, Andrade, NS, Wiedner, HJ, Vilca, SJ, Janczura, KJ, Bagheri, A, Al-Ali, H, Powell, SK, Brown, PT, Volmar, CH, Foster, TC, Zeier, ZR & Wahlestedt, CR 2019, 'Enhancement of BDNF expression and memory by HDAC inhibition requires BET bromodomain reader proteins', Journal of Neuroscience, vol. 39, no. 4, pp. 612-626. https://doi.org/10.1523/JNEUROSCI.1604-18.2018
Sartor, Gregory C. ; Malvezzi, Andrea M. ; Kumar, Ashok ; Andrade, Nadja S. ; Wiedner, Hannah J. ; Vilca, Samantha J. ; Janczura, Karolina J. ; Bagheri, Amir ; Al-Ali, Hassan ; Powell, Samuel K. ; Brown, Peyton T. ; Volmar, Claude H. ; Foster, Thomas C. ; Zeier, Zane R ; Wahlestedt, Claes R. / Enhancement of BDNF expression and memory by HDAC inhibition requires BET bromodomain reader proteins. In: Journal of Neuroscience. 2019 ; Vol. 39, No. 4. pp. 612-626.
@article{097dd30ffa8d4012ba73cc4ac26fb4c5,
title = "Enhancement of BDNF expression and memory by HDAC inhibition requires BET bromodomain reader proteins",
abstract = "Histone deacetylase (HDAC) inhibitors may have therapeutic utility in multiple neurological and psychiatric disorders, but the underlying mechanisms remain unclear. Here, we identify BRD4, a BET bromodomain reader of acetyl-lysine histones, as an essential component involved in potentiated expression of brain-derived neurotrophic factor (BDNF) and memory following HDAC inhibition. In in vitro studies, we reveal that pharmacological inhibition of BRD4 reversed the increase in BDNF mRNA induced by the class I/IIb HDAC inhibitor suberoylanilide hydroxamic acid (SAHA). Knock-down of HDAC2 and HDAC3, but not other HDACs, increased BDNF mRNA expression, whereas knock-down of BRD4 blocked these effects. Using dCas9-BRD4, locus-specific targeting of BRD4 to the BDNF promoter increased BDNF mRNA. In additional studies, RGFP966, a pharmacological inhibitor of HDAC3, elevated BDNF expression and BRD4 binding to the BDNF promoter, effects that were abrogated by JQ1 (an inhibitor of BRD4). Examining known epigenetic targets of BRD4 and HDAC3, we show that H4K5ac and H4K8ac modifications and H4K5ac enrichment at the BDNF promoter were elevated following RGFP966 treatment. In electrophysiological studies, JQ1 reversed RGFP966-induced enhancement of LTP in hippocampal slice preparations. Last, in behavioral studies, RGFP966 increased subthreshold novel object recognition memory and cocaine place preference in male C57BL/6 mice, effects that were reversed by cotreatment with JQ1. Together, these data reveal that BRD4 plays a key role in HDAC3 inhibitor-induced potentiation of BDNF expression, neuroplasticity, and memory.",
keywords = "BDNF, BET, BRD4, Bromodomain, HDAC3, JQ1",
author = "Sartor, {Gregory C.} and Malvezzi, {Andrea M.} and Ashok Kumar and Andrade, {Nadja S.} and Wiedner, {Hannah J.} and Vilca, {Samantha J.} and Janczura, {Karolina J.} and Amir Bagheri and Hassan Al-Ali and Powell, {Samuel K.} and Brown, {Peyton T.} and Volmar, {Claude H.} and Foster, {Thomas C.} and Zeier, {Zane R} and Wahlestedt, {Claes R}",
year = "2019",
month = "1",
day = "23",
doi = "10.1523/JNEUROSCI.1604-18.2018",
language = "English (US)",
volume = "39",
pages = "612--626",
journal = "Journal of Neuroscience",
issn = "0270-6474",
publisher = "Society for Neuroscience",
number = "4",

}

TY - JOUR

T1 - Enhancement of BDNF expression and memory by HDAC inhibition requires BET bromodomain reader proteins

AU - Sartor, Gregory C.

AU - Malvezzi, Andrea M.

AU - Kumar, Ashok

AU - Andrade, Nadja S.

AU - Wiedner, Hannah J.

AU - Vilca, Samantha J.

AU - Janczura, Karolina J.

AU - Bagheri, Amir

AU - Al-Ali, Hassan

AU - Powell, Samuel K.

AU - Brown, Peyton T.

AU - Volmar, Claude H.

AU - Foster, Thomas C.

AU - Zeier, Zane R

AU - Wahlestedt, Claes R

PY - 2019/1/23

Y1 - 2019/1/23

N2 - Histone deacetylase (HDAC) inhibitors may have therapeutic utility in multiple neurological and psychiatric disorders, but the underlying mechanisms remain unclear. Here, we identify BRD4, a BET bromodomain reader of acetyl-lysine histones, as an essential component involved in potentiated expression of brain-derived neurotrophic factor (BDNF) and memory following HDAC inhibition. In in vitro studies, we reveal that pharmacological inhibition of BRD4 reversed the increase in BDNF mRNA induced by the class I/IIb HDAC inhibitor suberoylanilide hydroxamic acid (SAHA). Knock-down of HDAC2 and HDAC3, but not other HDACs, increased BDNF mRNA expression, whereas knock-down of BRD4 blocked these effects. Using dCas9-BRD4, locus-specific targeting of BRD4 to the BDNF promoter increased BDNF mRNA. In additional studies, RGFP966, a pharmacological inhibitor of HDAC3, elevated BDNF expression and BRD4 binding to the BDNF promoter, effects that were abrogated by JQ1 (an inhibitor of BRD4). Examining known epigenetic targets of BRD4 and HDAC3, we show that H4K5ac and H4K8ac modifications and H4K5ac enrichment at the BDNF promoter were elevated following RGFP966 treatment. In electrophysiological studies, JQ1 reversed RGFP966-induced enhancement of LTP in hippocampal slice preparations. Last, in behavioral studies, RGFP966 increased subthreshold novel object recognition memory and cocaine place preference in male C57BL/6 mice, effects that were reversed by cotreatment with JQ1. Together, these data reveal that BRD4 plays a key role in HDAC3 inhibitor-induced potentiation of BDNF expression, neuroplasticity, and memory.

AB - Histone deacetylase (HDAC) inhibitors may have therapeutic utility in multiple neurological and psychiatric disorders, but the underlying mechanisms remain unclear. Here, we identify BRD4, a BET bromodomain reader of acetyl-lysine histones, as an essential component involved in potentiated expression of brain-derived neurotrophic factor (BDNF) and memory following HDAC inhibition. In in vitro studies, we reveal that pharmacological inhibition of BRD4 reversed the increase in BDNF mRNA induced by the class I/IIb HDAC inhibitor suberoylanilide hydroxamic acid (SAHA). Knock-down of HDAC2 and HDAC3, but not other HDACs, increased BDNF mRNA expression, whereas knock-down of BRD4 blocked these effects. Using dCas9-BRD4, locus-specific targeting of BRD4 to the BDNF promoter increased BDNF mRNA. In additional studies, RGFP966, a pharmacological inhibitor of HDAC3, elevated BDNF expression and BRD4 binding to the BDNF promoter, effects that were abrogated by JQ1 (an inhibitor of BRD4). Examining known epigenetic targets of BRD4 and HDAC3, we show that H4K5ac and H4K8ac modifications and H4K5ac enrichment at the BDNF promoter were elevated following RGFP966 treatment. In electrophysiological studies, JQ1 reversed RGFP966-induced enhancement of LTP in hippocampal slice preparations. Last, in behavioral studies, RGFP966 increased subthreshold novel object recognition memory and cocaine place preference in male C57BL/6 mice, effects that were reversed by cotreatment with JQ1. Together, these data reveal that BRD4 plays a key role in HDAC3 inhibitor-induced potentiation of BDNF expression, neuroplasticity, and memory.

KW - BDNF

KW - BET

KW - BRD4

KW - Bromodomain

KW - HDAC3

KW - JQ1

UR - http://www.scopus.com/inward/record.url?scp=85060400992&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060400992&partnerID=8YFLogxK

U2 - 10.1523/JNEUROSCI.1604-18.2018

DO - 10.1523/JNEUROSCI.1604-18.2018

M3 - Article

C2 - 30504275

AN - SCOPUS:85060400992

VL - 39

SP - 612

EP - 626

JO - Journal of Neuroscience

JF - Journal of Neuroscience

SN - 0270-6474

IS - 4

ER -